Beam Therapeutics Inc

NASDAQ:BEAM   4:00:00 PM EDT
34.07
-1.34 (-3.80%)
7:58:13 PM EDT: $34.30 +0.24 (+0.69%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.78B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$17.37 Million
Adjusted EPS-$1.39
See more estimates
10-Day MA$36.05
50-Day MA$30.98
200-Day MA$27.88
See more pivots

Beam Therapeutics Inc Stock, NASDAQ:BEAM

238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016
United States of America
Phone: +1.857.327.8775
Number of Employees: 436

Description

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.